Featured Research

from universities, journals, and other organizations

Basis For DNA Ejection From Single Phage Particles

Date:
March 12, 2005
Source:
Cell Press
Summary:
Studying phage, a primitive class of virus that infects bacteria by injecting its genomic DNA into host cells, researchers have gained insight into the driving force behind this poorly understood injection process, which has been proposed in the past to occur through the release of pressure accumulated within the viral particle itself.

Studying phage, a primitive class of virus that infects bacteria by injecting its genomic DNA into host cells, researchers have gained insight into the driving force behind this poorly understood injection process, which has been proposed in the past to occur through the release of pressure accumulated within the viral particle itself.

Almost all phages (also known as bacteriophages) are formed of a capsid structure, or head, in which the viral genome is packaged during morphogenesis, and a tail structure that ensures the attachment of the phage to the host bacteria. A common feature of phages is that during infection, only their genome is transferred to the bacterial host's cytoplasm, whereas the capsid and tail remain bound to the cell surface. This situation is very different from that found in most eukaryotic viruses, including those that infect humans, in that the envelope of these viruses fuses with the host plasma membrane so that the genome is delivered without directly contacting the membrane.

Phage nucleic acid transport poses a fascinating biophysical problem: Transport is unidirectional and linear; it concerns a unique molecule the size of which may represent 50 times that of the bacterium. The driving force for DNA transport is still poorly defined. It was hypothesized that the internal pressure built during packaging of the DNA in the phage capsid was responsible for DNA ejection. This pressure results from the condensation of the DNA during morphogenesis – for example, another group recently showed that the pressure at the final stage of encapsulation for a particular bacteriophage reached a value of 60 atomospheres, which is close to ten times the pressure inside a bottle of champagne. In the new work reported this week, researchers have evaluated whether the energy thus stored is sufficient to permit phage DNA ejection, or only to initiate that process.

The researchers used fluorescently labeled phage DNA to investigate in real time (and with a resolution time of 750 milliseconds) the dynamics of DNA ejection from single phages. The ejected DNA was measured at different stages of the ejection process after being stretched by applied hydrodynamic flow. The study demonstrated that DNA release is not an all-or-none process, but rather is unexpectedly complex. DNA release occurred at a very high rate, reaching 75,000 base pairs of DNA/sec, but in a stepwise fashion. Pausing times were observed during ejection, and ejection was transiently arrested at definite positions of the genome in close proximity to genetically defined physical interruptions in the DNA. The authors discuss the relevance of this stepwise ejection to the transfer of phage DNA in vivo.

###

Stéphanie Mangenot, Marion Hochrein, Joachim Rädler, and Lucienne Letellier: "Real-Time Imaging of DNA Ejection from Single Phage Particles"

The other members of the research team include Stéphanie Mangenot of the Laboratoire de Physique des Solides, UMR CNRS at Université Paris Sud; Marion Hochrein and Joachim Rädler of Ludwig Maximilian Universität; and Lucienne Letellier of the Institut de Biochimie et Biophysique Moléculaire et Cellulaire, UMR, CNRS at Université Paris Sud. This project was supported in part by the Centre National de la Recherche Scientifique program "Dynamique et Réactivité des Assemblages Biologiques" and by SFB 563 "Bioorganic Functional Systems on Solids."

Publishing in Current Biology, Volume 15, Number 5, March 8, 2005, pages 430-435. http://www.current-biology.com


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Basis For DNA Ejection From Single Phage Particles." ScienceDaily. ScienceDaily, 12 March 2005. <www.sciencedaily.com/releases/2005/03/050310103113.htm>.
Cell Press. (2005, March 12). Basis For DNA Ejection From Single Phage Particles. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/03/050310103113.htm
Cell Press. "Basis For DNA Ejection From Single Phage Particles." ScienceDaily. www.sciencedaily.com/releases/2005/03/050310103113.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins